HDAC8 Inhibition Specifically Targets Inv(16) Acute Myeloid Leukemic Stem Cells by Restoring p53 Acetylation

Jing Qi, Sandeep Singh, Wei Kai Hua, Qi Cai, Shi Wei Chao, Ling Li, Hongjun Liu, Yinwei Ho, Tinisha McDonald, Allen Lin, Guido Marcucci, Ravi Bhatia, Wei Jan Huang, Chung I. Chang, Ya Huei Kuo

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Acute myeloid leukemia (AML) is driven and sustained by leukemia stem cells (LSCs) with unlimited self-renewal capacity and resistance to chemotherapy. Mutation in the TP53 tumor suppressor is relatively rare in de novo AML; however, p53 can be regulated through post-translational mechanisms. Here, we show that p53 activity is inhibited in inv(16)+ AML LSCs via interactions with the CBFβ-SMMHC (CM) fusion protein and histone deacetylase 8 (HDAC8). HDAC8 aberrantly deacetylates p53 and promotes LSC transformation and maintenance. HDAC8 deficiency or inhibition using HDAC8-selective inhibitors (HDAC8i) effectively restores p53 acetylation and activity. Importantly, HDAC8 inhibition induces apoptosis in inv(16)+ AML CD34+ cells, while sparing the normal hematopoietic stem cells. Furthermore, in vivo HDAC8i administration profoundly diminishes AML propagation and abrogates leukemia-initiating capacity of both murine and patient-derived LSCs. This study elucidates an HDAC8-mediated p53-inactivating mechanism promoting LSC activity and highlights HDAC8 inhibition as a promising approach to selectively target inv(16)+ LSCs.

Original languageEnglish
Pages (from-to)597-610
Number of pages14
JournalCell Stem Cell
Volume17
Issue number5
DOIs
Publication statusPublished - Nov 5 2015

Fingerprint

Myeloid Progenitor Cells
Histone Deacetylases
Acetylation
Leukemia
Acute Myeloid Leukemia
Stem Cells
Hematopoietic Stem Cells
Cell Communication
Maintenance
Apoptosis
Drug Therapy
Mutation

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Medicine
  • Genetics

Cite this

HDAC8 Inhibition Specifically Targets Inv(16) Acute Myeloid Leukemic Stem Cells by Restoring p53 Acetylation. / Qi, Jing; Singh, Sandeep; Hua, Wei Kai; Cai, Qi; Chao, Shi Wei; Li, Ling; Liu, Hongjun; Ho, Yinwei; McDonald, Tinisha; Lin, Allen; Marcucci, Guido; Bhatia, Ravi; Huang, Wei Jan; Chang, Chung I.; Kuo, Ya Huei.

In: Cell Stem Cell, Vol. 17, No. 5, 05.11.2015, p. 597-610.

Research output: Contribution to journalArticle

Qi, J, Singh, S, Hua, WK, Cai, Q, Chao, SW, Li, L, Liu, H, Ho, Y, McDonald, T, Lin, A, Marcucci, G, Bhatia, R, Huang, WJ, Chang, CI & Kuo, YH 2015, 'HDAC8 Inhibition Specifically Targets Inv(16) Acute Myeloid Leukemic Stem Cells by Restoring p53 Acetylation', Cell Stem Cell, vol. 17, no. 5, pp. 597-610. https://doi.org/10.1016/j.stem.2015.08.004
Qi, Jing ; Singh, Sandeep ; Hua, Wei Kai ; Cai, Qi ; Chao, Shi Wei ; Li, Ling ; Liu, Hongjun ; Ho, Yinwei ; McDonald, Tinisha ; Lin, Allen ; Marcucci, Guido ; Bhatia, Ravi ; Huang, Wei Jan ; Chang, Chung I. ; Kuo, Ya Huei. / HDAC8 Inhibition Specifically Targets Inv(16) Acute Myeloid Leukemic Stem Cells by Restoring p53 Acetylation. In: Cell Stem Cell. 2015 ; Vol. 17, No. 5. pp. 597-610.
@article{97339743c04d4e25942bc0c920bf8a10,
title = "HDAC8 Inhibition Specifically Targets Inv(16) Acute Myeloid Leukemic Stem Cells by Restoring p53 Acetylation",
abstract = "Acute myeloid leukemia (AML) is driven and sustained by leukemia stem cells (LSCs) with unlimited self-renewal capacity and resistance to chemotherapy. Mutation in the TP53 tumor suppressor is relatively rare in de novo AML; however, p53 can be regulated through post-translational mechanisms. Here, we show that p53 activity is inhibited in inv(16)+ AML LSCs via interactions with the CBFβ-SMMHC (CM) fusion protein and histone deacetylase 8 (HDAC8). HDAC8 aberrantly deacetylates p53 and promotes LSC transformation and maintenance. HDAC8 deficiency or inhibition using HDAC8-selective inhibitors (HDAC8i) effectively restores p53 acetylation and activity. Importantly, HDAC8 inhibition induces apoptosis in inv(16)+ AML CD34+ cells, while sparing the normal hematopoietic stem cells. Furthermore, in vivo HDAC8i administration profoundly diminishes AML propagation and abrogates leukemia-initiating capacity of both murine and patient-derived LSCs. This study elucidates an HDAC8-mediated p53-inactivating mechanism promoting LSC activity and highlights HDAC8 inhibition as a promising approach to selectively target inv(16)+ LSCs.",
author = "Jing Qi and Sandeep Singh and Hua, {Wei Kai} and Qi Cai and Chao, {Shi Wei} and Ling Li and Hongjun Liu and Yinwei Ho and Tinisha McDonald and Allen Lin and Guido Marcucci and Ravi Bhatia and Huang, {Wei Jan} and Chang, {Chung I.} and Kuo, {Ya Huei}",
year = "2015",
month = "11",
day = "5",
doi = "10.1016/j.stem.2015.08.004",
language = "English",
volume = "17",
pages = "597--610",
journal = "Cell Stem Cell",
issn = "1934-5909",
publisher = "Cell Press",
number = "5",

}

TY - JOUR

T1 - HDAC8 Inhibition Specifically Targets Inv(16) Acute Myeloid Leukemic Stem Cells by Restoring p53 Acetylation

AU - Qi, Jing

AU - Singh, Sandeep

AU - Hua, Wei Kai

AU - Cai, Qi

AU - Chao, Shi Wei

AU - Li, Ling

AU - Liu, Hongjun

AU - Ho, Yinwei

AU - McDonald, Tinisha

AU - Lin, Allen

AU - Marcucci, Guido

AU - Bhatia, Ravi

AU - Huang, Wei Jan

AU - Chang, Chung I.

AU - Kuo, Ya Huei

PY - 2015/11/5

Y1 - 2015/11/5

N2 - Acute myeloid leukemia (AML) is driven and sustained by leukemia stem cells (LSCs) with unlimited self-renewal capacity and resistance to chemotherapy. Mutation in the TP53 tumor suppressor is relatively rare in de novo AML; however, p53 can be regulated through post-translational mechanisms. Here, we show that p53 activity is inhibited in inv(16)+ AML LSCs via interactions with the CBFβ-SMMHC (CM) fusion protein and histone deacetylase 8 (HDAC8). HDAC8 aberrantly deacetylates p53 and promotes LSC transformation and maintenance. HDAC8 deficiency or inhibition using HDAC8-selective inhibitors (HDAC8i) effectively restores p53 acetylation and activity. Importantly, HDAC8 inhibition induces apoptosis in inv(16)+ AML CD34+ cells, while sparing the normal hematopoietic stem cells. Furthermore, in vivo HDAC8i administration profoundly diminishes AML propagation and abrogates leukemia-initiating capacity of both murine and patient-derived LSCs. This study elucidates an HDAC8-mediated p53-inactivating mechanism promoting LSC activity and highlights HDAC8 inhibition as a promising approach to selectively target inv(16)+ LSCs.

AB - Acute myeloid leukemia (AML) is driven and sustained by leukemia stem cells (LSCs) with unlimited self-renewal capacity and resistance to chemotherapy. Mutation in the TP53 tumor suppressor is relatively rare in de novo AML; however, p53 can be regulated through post-translational mechanisms. Here, we show that p53 activity is inhibited in inv(16)+ AML LSCs via interactions with the CBFβ-SMMHC (CM) fusion protein and histone deacetylase 8 (HDAC8). HDAC8 aberrantly deacetylates p53 and promotes LSC transformation and maintenance. HDAC8 deficiency or inhibition using HDAC8-selective inhibitors (HDAC8i) effectively restores p53 acetylation and activity. Importantly, HDAC8 inhibition induces apoptosis in inv(16)+ AML CD34+ cells, while sparing the normal hematopoietic stem cells. Furthermore, in vivo HDAC8i administration profoundly diminishes AML propagation and abrogates leukemia-initiating capacity of both murine and patient-derived LSCs. This study elucidates an HDAC8-mediated p53-inactivating mechanism promoting LSC activity and highlights HDAC8 inhibition as a promising approach to selectively target inv(16)+ LSCs.

UR - http://www.scopus.com/inward/record.url?scp=84947865743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947865743&partnerID=8YFLogxK

U2 - 10.1016/j.stem.2015.08.004

DO - 10.1016/j.stem.2015.08.004

M3 - Article

C2 - 26387755

AN - SCOPUS:84947865743

VL - 17

SP - 597

EP - 610

JO - Cell Stem Cell

JF - Cell Stem Cell

SN - 1934-5909

IS - 5

ER -